Novel antitrypanosomal agents
Trypanosomes are the causative agents of Chagas disease in Central and South America and sleeping sickness in sub-Saharan Africa. The current chemotherapy of the human trypanosomiases relies on only six drugs, five of which were developed > 30 years ago. In addition, these drugs display undesirab...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on investigational drugs 2005-08, Vol.14 (8), p.939-955 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 955 |
|---|---|
| container_issue | 8 |
| container_start_page | 939 |
| container_title | Expert opinion on investigational drugs |
| container_volume | 14 |
| creator | Steverding, Dietmar Tyler, Kevin M |
| description | Trypanosomes are the causative agents of Chagas disease in Central and South America and sleeping sickness in sub-Saharan Africa. The current chemotherapy of the human trypanosomiases relies on only six drugs, five of which were developed > 30 years ago. In addition, these drugs display undesirable toxic side effects and the emergence of drug-resistant trypanosomes has been reported. Therefore, the development of new drugs in the treatment of Chagas disease and sleeping sickness is urgently required. This article summarises the recent progress in identifying novel lead compounds for antitrypanosomal chemotherapy. Particular emphasis is placed on those agents showing promising, selective antitrypanosomal activity. |
| doi_str_mv | 10.1517/13543784.14.8.939 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_20384586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20384586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-b758fcb7a511e64c255b25f7f77afb35b6a313f31552813f6aa03bac06fae5bc3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EolD4ABYgVuwS7Dh-RLBBFS-pgg2srbFr01RJXOwE1L_HVYsQm65mND73yjoInRGcE0bENaGspEKWOSlzmVe02kNHRJRlJjiT-2lP79kaGKHjGBcYF7hi9BCNCMcMC1kdofMX_2WbS-j6ug-rJXQ--hbS4cN2fTxBBw6aaE-3c4zeH-7fJk_Z9PXxeXI3zQzlrM-0YNIZLYARYnlpCsZ0wZxwQoDTlGkOlFBHCWOFTAsHwFSDwdyBZdrQMbra9C6D_xxs7FVbR2ObBjrrh6gKTGXJJE8g2YAm-BiDdWoZ6hbCShGs1k7UrxNFSiVVcpIyF9vyQbd29pfYSkjA7QaoO-dDC98-NDPVw6rxwQXoTB0V3dV_8y8-t9D0cwPBqoUfQpfE7fjdD4Bngi4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20384586</pqid></control><display><type>article</type><title>Novel antitrypanosomal agents</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Access via Taylor & Francis</source><creator>Steverding, Dietmar ; Tyler, Kevin M</creator><creatorcontrib>Steverding, Dietmar ; Tyler, Kevin M</creatorcontrib><description>Trypanosomes are the causative agents of Chagas disease in Central and South America and sleeping sickness in sub-Saharan Africa. The current chemotherapy of the human trypanosomiases relies on only six drugs, five of which were developed > 30 years ago. In addition, these drugs display undesirable toxic side effects and the emergence of drug-resistant trypanosomes has been reported. Therefore, the development of new drugs in the treatment of Chagas disease and sleeping sickness is urgently required. This article summarises the recent progress in identifying novel lead compounds for antitrypanosomal chemotherapy. Particular emphasis is placed on those agents showing promising, selective antitrypanosomal activity.</description><identifier>ISSN: 1354-3784</identifier><identifier>EISSN: 1744-7658</identifier><identifier>DOI: 10.1517/13543784.14.8.939</identifier><identifier>PMID: 16050789</identifier><language>eng</language><publisher>England: Ashley Publications Ltd</publisher><subject>Animals ; anti-trypanosomal agents ; anti-tubulin agents ; Chagas Disease - drug therapy ; Chagas Disease - metabolism ; Chagas' disease ; cysteine protease inhibitors ; DNA topoisomerase inhibitors ; Drugs, Investigational - chemistry ; Drugs, Investigational - pharmacology ; Drugs, Investigational - therapeutic use ; Humans ; proteasome inhibitors ; sleeping sickness ; sterol biosynthesis inhibitors ; Trypanocidal Agents - chemistry ; Trypanocidal Agents - pharmacology ; Trypanocidal Agents - therapeutic use ; Trypanosoma ; Trypanosoma brucei ; Trypanosoma cruzi ; Trypanosomiasis, African - drug therapy ; Trypanosomiasis, African - metabolism</subject><ispartof>Expert opinion on investigational drugs, 2005-08, Vol.14 (8), p.939-955</ispartof><rights>Ashley Publications Ltd 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-b758fcb7a511e64c255b25f7f77afb35b6a313f31552813f6aa03bac06fae5bc3</citedby><cites>FETCH-LOGICAL-c365t-b758fcb7a511e64c255b25f7f77afb35b6a313f31552813f6aa03bac06fae5bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/13543784.14.8.939$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/13543784.14.8.939$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,59753,60436,60542</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16050789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steverding, Dietmar</creatorcontrib><creatorcontrib>Tyler, Kevin M</creatorcontrib><title>Novel antitrypanosomal agents</title><title>Expert opinion on investigational drugs</title><addtitle>Expert Opin Investig Drugs</addtitle><description>Trypanosomes are the causative agents of Chagas disease in Central and South America and sleeping sickness in sub-Saharan Africa. The current chemotherapy of the human trypanosomiases relies on only six drugs, five of which were developed > 30 years ago. In addition, these drugs display undesirable toxic side effects and the emergence of drug-resistant trypanosomes has been reported. Therefore, the development of new drugs in the treatment of Chagas disease and sleeping sickness is urgently required. This article summarises the recent progress in identifying novel lead compounds for antitrypanosomal chemotherapy. Particular emphasis is placed on those agents showing promising, selective antitrypanosomal activity.</description><subject>Animals</subject><subject>anti-trypanosomal agents</subject><subject>anti-tubulin agents</subject><subject>Chagas Disease - drug therapy</subject><subject>Chagas Disease - metabolism</subject><subject>Chagas' disease</subject><subject>cysteine protease inhibitors</subject><subject>DNA topoisomerase inhibitors</subject><subject>Drugs, Investigational - chemistry</subject><subject>Drugs, Investigational - pharmacology</subject><subject>Drugs, Investigational - therapeutic use</subject><subject>Humans</subject><subject>proteasome inhibitors</subject><subject>sleeping sickness</subject><subject>sterol biosynthesis inhibitors</subject><subject>Trypanocidal Agents - chemistry</subject><subject>Trypanocidal Agents - pharmacology</subject><subject>Trypanocidal Agents - therapeutic use</subject><subject>Trypanosoma</subject><subject>Trypanosoma brucei</subject><subject>Trypanosoma cruzi</subject><subject>Trypanosomiasis, African - drug therapy</subject><subject>Trypanosomiasis, African - metabolism</subject><issn>1354-3784</issn><issn>1744-7658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EolD4ABYgVuwS7Dh-RLBBFS-pgg2srbFr01RJXOwE1L_HVYsQm65mND73yjoInRGcE0bENaGspEKWOSlzmVe02kNHRJRlJjiT-2lP79kaGKHjGBcYF7hi9BCNCMcMC1kdofMX_2WbS-j6ug-rJXQ--hbS4cN2fTxBBw6aaE-3c4zeH-7fJk_Z9PXxeXI3zQzlrM-0YNIZLYARYnlpCsZ0wZxwQoDTlGkOlFBHCWOFTAsHwFSDwdyBZdrQMbra9C6D_xxs7FVbR2ObBjrrh6gKTGXJJE8g2YAm-BiDdWoZ6hbCShGs1k7UrxNFSiVVcpIyF9vyQbd29pfYSkjA7QaoO-dDC98-NDPVw6rxwQXoTB0V3dV_8y8-t9D0cwPBqoUfQpfE7fjdD4Bngi4</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Steverding, Dietmar</creator><creator>Tyler, Kevin M</creator><general>Ashley Publications Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope></search><sort><creationdate>20050801</creationdate><title>Novel antitrypanosomal agents</title><author>Steverding, Dietmar ; Tyler, Kevin M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-b758fcb7a511e64c255b25f7f77afb35b6a313f31552813f6aa03bac06fae5bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>anti-trypanosomal agents</topic><topic>anti-tubulin agents</topic><topic>Chagas Disease - drug therapy</topic><topic>Chagas Disease - metabolism</topic><topic>Chagas' disease</topic><topic>cysteine protease inhibitors</topic><topic>DNA topoisomerase inhibitors</topic><topic>Drugs, Investigational - chemistry</topic><topic>Drugs, Investigational - pharmacology</topic><topic>Drugs, Investigational - therapeutic use</topic><topic>Humans</topic><topic>proteasome inhibitors</topic><topic>sleeping sickness</topic><topic>sterol biosynthesis inhibitors</topic><topic>Trypanocidal Agents - chemistry</topic><topic>Trypanocidal Agents - pharmacology</topic><topic>Trypanocidal Agents - therapeutic use</topic><topic>Trypanosoma</topic><topic>Trypanosoma brucei</topic><topic>Trypanosoma cruzi</topic><topic>Trypanosomiasis, African - drug therapy</topic><topic>Trypanosomiasis, African - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steverding, Dietmar</creatorcontrib><creatorcontrib>Tyler, Kevin M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Expert opinion on investigational drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steverding, Dietmar</au><au>Tyler, Kevin M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel antitrypanosomal agents</atitle><jtitle>Expert opinion on investigational drugs</jtitle><addtitle>Expert Opin Investig Drugs</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>14</volume><issue>8</issue><spage>939</spage><epage>955</epage><pages>939-955</pages><issn>1354-3784</issn><eissn>1744-7658</eissn><abstract>Trypanosomes are the causative agents of Chagas disease in Central and South America and sleeping sickness in sub-Saharan Africa. The current chemotherapy of the human trypanosomiases relies on only six drugs, five of which were developed > 30 years ago. In addition, these drugs display undesirable toxic side effects and the emergence of drug-resistant trypanosomes has been reported. Therefore, the development of new drugs in the treatment of Chagas disease and sleeping sickness is urgently required. This article summarises the recent progress in identifying novel lead compounds for antitrypanosomal chemotherapy. Particular emphasis is placed on those agents showing promising, selective antitrypanosomal activity.</abstract><cop>England</cop><pub>Ashley Publications Ltd</pub><pmid>16050789</pmid><doi>10.1517/13543784.14.8.939</doi><tpages>17</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1354-3784 |
| ispartof | Expert opinion on investigational drugs, 2005-08, Vol.14 (8), p.939-955 |
| issn | 1354-3784 1744-7658 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20384586 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Access via Taylor & Francis |
| subjects | Animals anti-trypanosomal agents anti-tubulin agents Chagas Disease - drug therapy Chagas Disease - metabolism Chagas' disease cysteine protease inhibitors DNA topoisomerase inhibitors Drugs, Investigational - chemistry Drugs, Investigational - pharmacology Drugs, Investigational - therapeutic use Humans proteasome inhibitors sleeping sickness sterol biosynthesis inhibitors Trypanocidal Agents - chemistry Trypanocidal Agents - pharmacology Trypanocidal Agents - therapeutic use Trypanosoma Trypanosoma brucei Trypanosoma cruzi Trypanosomiasis, African - drug therapy Trypanosomiasis, African - metabolism |
| title | Novel antitrypanosomal agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T09%3A09%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20antitrypanosomal%20agents&rft.jtitle=Expert%20opinion%20on%20investigational%20drugs&rft.au=Steverding,%20Dietmar&rft.date=2005-08-01&rft.volume=14&rft.issue=8&rft.spage=939&rft.epage=955&rft.pages=939-955&rft.issn=1354-3784&rft.eissn=1744-7658&rft_id=info:doi/10.1517/13543784.14.8.939&rft_dat=%3Cproquest_pubme%3E20384586%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20384586&rft_id=info:pmid/16050789&rfr_iscdi=true |